In vivo dose threshold effect of adenovirus-mediated Factor VIII gene therapy in hemophiliac mice

Molecular Therapy

Volumn 2, Issue 3, 2000, Pages 223-232

  Bristol, J Andrew ^a   Shirley, Pamela ^a   Idamakanti, Neeraja ^a   Kaleko, Michael ^a   Connelly, Sheila ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Adenovirus; Dose; Factor VIII; Gene therapy; Hemophilia; Immunology; In vivo; Murine; Nonreplicating; Threshold

Indexed keywords

ADENOVIRIDAE; MURINAE;

BLOOD CLOTTING FACTOR 8;

ADENOVIRUS; ANIMAL; ARTICLE; GENE THERAPY; GENE VECTOR; GENETICS; HEMOPHILIA A; HUMAN; MOUSE;

ADENOVIRIDAE; ANIMALS; FACTOR VIII; GENE THERAPY; GENETIC VECTORS; HEMOPHILIA A; HUMANS; MICE;

EID: 0034266550     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2000.0120     Document Type: Article

References (46)

1. Horwitz, M. S. (1996). Adenoviruses. In Fields Virology (B. N. Fields, D. M. Knipe, and P. M. Howley, Eds.), 3rd ed., pp. 2149-2171. Lippincott-Raven, Philadelphia, PA.
2. Adam, E., Nasz, I., and Lengyel, A. (1996). Characterization of adenovirus hexons by their epitope composition. Arch. Virol. 141: 1891-1907.
3. Pring-Åkerblom, P., Heim, A., and Trijssenaar, F. E. J. (1998). Molecular characterization of hemagglutination domains on the fibers of subgenus D adenoviruses. J. Virol. 72: 2297-2304.
4. Benihoud, K., Yeh, P., and Perricaudet, M. (1999). Adenovirus vectors for gene delivery. Curr. Opin. Biotechnol. 10: 440-447.
5. Brenner, M. (1999). Gene transfer by adenovectors. Blood 94: 3965-3967.
6. Zhang, W. W. (1999). Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther. 6: 113-138.
7. Gorziglia, M. I., et al. (1999). Generation of an adenovirus vector lacking E1, E2a, E3, and all of E4 except open reading frame 3. J. Virol. 73: 6048-6055.
8. Lozier, J. N., Metzger, M. E., Donahue, R. E., and Morgan, R. A. (1999). Adenovirus-mediated expression of human coagulation Factor IX in the rhesus macaque is associated with dose-limiting toxicity. Blood 94: 3968-3975.
9. Rojas-Martinez, A., Wyde, P. R., Montgomery, C. A., Chen, S. H., Woo, S. L., and Aguilar-Cordova, E. (1998). Distribution, persistency, toxicity, and lack of replication of an E1A-deficient adenoviral vector after intracardiac delivery in the cotton rat. Cancer Gene Ther. 5: 365-370.
10. Morsy, M. A., et al. (1998). An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc. Natl. Acad. Sci. USA 95: 7866-7871.
11. Lusky, M., et al. (1998). In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J. Virol. 72: 2022-2032.
12. Schiedner, G., et al. (1998). Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat. Genet. 18: 180-183.
13. Gorziglia, M. I., et al. (1996). Elimination of both E1 and E2a from adenovirus vectors further improves prospects for in vivo human gene therapy. J. Virol. 70: 4173-4178.
14. Gao, G. P., Yang, Y., and Wilson, J. M. (1996). Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J. Virol. 70: 8934-8943.
15. Yang, Y., Nunes, F. A., Berencsi, K., Gonczol, E., Engelhardt, J. F., and Wilson, J. M. (1994). Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat. Genet. 7: 362-369.
16. Hardy, S., Kitamura, M., Harris-Stansil, T., Dai, Y., and Phipps, M. L. (1997). Construction of adenovirus vectors through Cre-lox recombination. J. Virol. 71: 1842-1849.
17. Connelly, S., et al. (1998). Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood 91: 3273-3281.
18. Dusetti, N. J., et al. (1997). The pancreatitis-associated protein I promoter allows targeting to the pancreas of a foreign gene, whose expression is up-regulated during pancreatic inflammation. J. Biol. Chem. 272: 5800-5804.
19. Shi, Q., Wang, Y., and Worton, R. (1997). Modulation of the specificity and activity of a cellular promoter in an adenoviral vector. Hum. Gene Ther. 8: 403-410.
20. Pastore, L., et al. (1999). Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. Hum. Gene Ther. 10: 1773-1781.
21. Roy, S., Shirley, P. S., McClelland, A., and Kaleko, M. (1998). Circumvention of immunity to the adenovirus major coat protein hexon. J. Virol. 72: 6875-6879.
22. Douglas, J. T., et al. (1999). A system for the propagation of adenoviral vectors with genetically modified receptor specificities. Nat. Biotechnol. 17:470-475.
23. Engelhardt, J. F., Ye, X., Doranz, B., and Wilson, J. M. (1994). Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. USA 91: 6196-6200.
24. Jooss, K., Ertl, H. C. J., and Wilson, J. M. (1998). Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver. J. Virol. 72: 2945-2954.
25. Yang, Y., Nunes, F. A., Berencsi, K., Furth, E., Gonczol, E., and Wilson, J. M. (1994). Cellular immunity to viral antigens limits E1 -deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA 91: 4407-4411.
26. Yang, Y., Jooss, K. U., Su, Q., Ertl, H. C. J., and Wilson, J. M. (1996). Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther. 3: 137-144.
27. Chirmule, N., Hughes, J. V., Gao, G-P., Raper, S. E., and Wilson, J. M. (1998). Role of E4 in eliciting CD4 T-cell and B-cell responses to adenovirus vectors delivered to murine and nonhuman primate lungs. J. Virol. 72: 6138-6145.
28. Papp, Z., Babiuk, L. A., and Baca-Estrada, M. E. (1999). Antigen-specific cytokine and antibody isotype profiles induced by mucosal and systemic immunization with recombinant adenoviruses. Viral Immunol. 12: 107-116.
29. Chirmule, N., Propert, K. J., Magosin, S. A., Qian, Y., Qian, R., and Wilson, J. M. (1999). Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 6: 1574-1583.
30. Gahery-Segard, H., et al. (1997). Humoral immune response to the capsid components of recombinant adenoviruses: routes of immunization modulate virus-induced Ig subclass shifts. Eur. J. Immunol. 27: 653-659.
31. Gahery-Segard, H., et al. (1998). Immune response to recombinant capsid proteins of adenovirus in humans: Antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J. Virol. 72: 2388-2397.
32. Harvey, B.-G., et al. (1999). Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J. Virol. 73: 6729-6742.
33. Bi, L., Lawler, A. M., Antonarakis, S. E., High, K. A., Gerhart, J. D., and Kazazian, H. H. (1995). Targeted disruption of the mouse Factor VIII gene produces a model of haemophilia A. Nat. Genet. 10: 119-121.
34. Lollar, P., et al. (1994). Inhibition of human Factor VIIIa by anti-A2 subunit antibodies. J. Clin. Invest. 93: 2497-2504.
35. Barr, D., et al. (1995). Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: Comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther. 2: 151-155.
36. Qian, J., Borovok, M., Bi, L., Kazazian, H. H., and Hoyer, L. W. (1999). Inhibitor antibody development and T cell response to human Factor VIII in murine hemophilia A. Thromb. Haemost. 81: 240-244.
37. Balagué, C., et al. (2000) Sustained high-level expression of full-length human Factor VIII and restoration of clotting activity in hemophiliac mice using a minimal adenovirus vector. Blood 95: 820-828.
38. O'Neal, W. K., et al. (1998) Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing alpha 1-antitrypsin after systemic delivery. Hum. Gene Ther. 9: 1587〈Q4〉.
39. Muruve, D. A., Barnes, M. J., Stillman, I. E., and Libermann, T. A. (1999). Adenoviral gene therapy leads to a rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in mice. Hum. Gene Ther. 10: 965-976.
40. Otake, K., Ennist, D. L., Harrod, K., and Trapnell, B. C. (1998). Nonspecific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses. Hum. Gene Ther. 9: 2207-2222.
41. Worgall, S., Leopold, P. L., Wolff, G., Ferris, B., Van Roijen, N., and Crystal, R. G. (1997). Role of alveolar macrophages in rapid elimination of adenovirus vectors administered to the epithelial surface of the respiratory tract. Hum. Gene Ther. 8: 1675-1684.
42. Connelly, S., Gardner, J. M., Lyons, R. M., McClelland, A., and Kaleko, M. (1996). Sustained expression of therapeutic levels of human Factor VIII in mice. Blood 87: 4671-4677.
43. Connelly, S., Andrews, J. L., Gallo-Penn, A. M., Tagliavacca, L., Kaufman, R. J., and Kaleko, M. (1999). Evaluation of an adenoviral vector encoding full-length human Factor VIII in hemophiliac mice. Thromb. Haemost. 81: 234-239.
44. Gallo-Penn, A. M., et al. (1999). In vivo evaluation of an adenoviral vector encoding canine FactorVIII: High-level, sustained expression in hemophiliac mice. Hum. Gene Ther. 10: 1791-1802.
45. Brann, T., Kayda, D., Lyons, R. M., Shirley, P., Roy, S., Kaleko, M., and Smith, T. (1999). Adenoviral vector-mediated expression of physiologic levels of human Factor VIII in nonhuman primates. Hum. Gene Ther. 10: 2999-3011.
46. Alemany, R., Suzuki, K., and Curiel, D. T. (2000). Blood clearance of adenovirus type 5 in mice. Mol. Ther. 1: S26-S27.